News | February 12, 2009

Positive Data on Stem Cell Treatment for Acute MI Reported

February 12, 2009 - Osiris Therapeutics Inc. yesterday announced final two-year results for the company's trial evaluating Prochymal — a proprietary formulation of adult stem cells — for the treatment of acute myocardial infarction.

Prochymal is designed to provide therapeutic benefit by controlling inflammation, promoting tissue regeneration and preventing scar formation. Prochymal is a preparation of mesenchymal stem cells specially formulated for intravenous infusion. The stem cells are obtained from the bone marrow of healthy adult donors.

The double-blind, placebo-controlled study of 53 patients, which evaluated safety and preliminary efficacy, found heart attack patients receiving the intravenous therapy had lower rates of adverse events and significantly improved heart function.

Study findings included:

- The trial met its primary endpoint demonstrating safety of Prochymal in the acute MI setting.
- Patients receiving Prochymal had fewer adverse events compared to placebo.
- A lower percentage of patients treated with Prochymal required repeat hospitalization.
- Patients receiving Prochymal had reduced incidence of cardiac arrhythmia.
- Patients receiving Prochymal had a significant and durable improvement in cardiac function.

"This placebo controlled study was truly first of its kind and the data produced is promising," said Timothy Henry, M.D., director of research at the Minneapolis Heart Institute Foundation at Abbott Northwestern. "It clearly suggests that allogeneic adult stem cells have significant potential to improve recovery following a heart attack and can prevent long term adverse effects. Given the fact that we can administer this drug through a standard IV in an acute setting, Prochymal could become an integral part of standard of care for treatment of heart attacks everywhere.”

For more information: www.Osiris.com.

Related Content

Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG
News | Stem Cell Therapies | January 17, 2018
Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance...
News | Stem Cell Therapies | October 24, 2017
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate compani
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies | September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies | August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

News | Stem Cell Therapies | June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina
News | Stem Cell Therapies | May 12, 2017
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a...
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies | April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies | February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
News | Stem Cell Therapies | January 09, 2017
BioCardia Inc. announced in December the issuance of United States Patent No. 9,517,199 relating to a method of...
Overlay Init